Análisis de costo- utilidad de Baricitinib y Upadacitinib comparado con Dupilumab en monoterapia en pacientes adultos con dermatitis atópica moderada a severa en Colombia
La dermatitis atópica (DA) es una enfermedad de la piel con un alto impacto social y económico tanto para el sistema de salud como para el paciente, en Colombia las moléculas de Dupilumab, Upadacitinib y Baricitinib tienen aprobación por el Invima para su uso en casos de enfermedad moderada a severa...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2023
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- spa
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/41836
- Acceso en línea:
- https://doi.org/10.48713/10336_41836
https://repository.urosario.edu.co/handle/10336/41836
- Palabra clave:
- Dermatitis atópica
Biológicos
Ihibidores JAK
Costos
Análisis de costos
Atopic dermatitis
Biologics
JAK inhibitors
Cost
Cost analysis
- Rights
- License
- Attribution-NoDerivatives 4.0 International
| id |
EDOCUR2_2c0848c20072718c79ff3682c2c5ede0 |
|---|---|
| oai_identifier_str |
oai:repository.urosario.edu.co:10336/41836 |
| network_acronym_str |
EDOCUR2 |
| network_name_str |
Repositorio EdocUR - U. Rosario |
| repository_id_str |
|
| dc.title.none.fl_str_mv |
Análisis de costo- utilidad de Baricitinib y Upadacitinib comparado con Dupilumab en monoterapia en pacientes adultos con dermatitis atópica moderada a severa en Colombia |
| dc.title.TranslatedTitle.none.fl_str_mv |
Cost-utility analysis of Baricitinib and Upadacitinib compared with Dupilumab monotherapy in adult patients with moderate to severe atopic dermatitis in Colombia |
| title |
Análisis de costo- utilidad de Baricitinib y Upadacitinib comparado con Dupilumab en monoterapia en pacientes adultos con dermatitis atópica moderada a severa en Colombia |
| spellingShingle |
Análisis de costo- utilidad de Baricitinib y Upadacitinib comparado con Dupilumab en monoterapia en pacientes adultos con dermatitis atópica moderada a severa en Colombia Dermatitis atópica Biológicos Ihibidores JAK Costos Análisis de costos Atopic dermatitis Biologics JAK inhibitors Cost Cost analysis |
| title_short |
Análisis de costo- utilidad de Baricitinib y Upadacitinib comparado con Dupilumab en monoterapia en pacientes adultos con dermatitis atópica moderada a severa en Colombia |
| title_full |
Análisis de costo- utilidad de Baricitinib y Upadacitinib comparado con Dupilumab en monoterapia en pacientes adultos con dermatitis atópica moderada a severa en Colombia |
| title_fullStr |
Análisis de costo- utilidad de Baricitinib y Upadacitinib comparado con Dupilumab en monoterapia en pacientes adultos con dermatitis atópica moderada a severa en Colombia |
| title_full_unstemmed |
Análisis de costo- utilidad de Baricitinib y Upadacitinib comparado con Dupilumab en monoterapia en pacientes adultos con dermatitis atópica moderada a severa en Colombia |
| title_sort |
Análisis de costo- utilidad de Baricitinib y Upadacitinib comparado con Dupilumab en monoterapia en pacientes adultos con dermatitis atópica moderada a severa en Colombia |
| dc.contributor.advisor.none.fl_str_mv |
Bareño Silva, José |
| dc.subject.none.fl_str_mv |
Dermatitis atópica Biológicos Ihibidores JAK Costos Análisis de costos |
| topic |
Dermatitis atópica Biológicos Ihibidores JAK Costos Análisis de costos Atopic dermatitis Biologics JAK inhibitors Cost Cost analysis |
| dc.subject.keyword.none.fl_str_mv |
Atopic dermatitis Biologics JAK inhibitors Cost Cost analysis |
| description |
La dermatitis atópica (DA) es una enfermedad de la piel con un alto impacto social y económico tanto para el sistema de salud como para el paciente, en Colombia las moléculas de Dupilumab, Upadacitinib y Baricitinib tienen aprobación por el Invima para su uso en casos de enfermedad moderada a severa. Dupilumab continúa siendo la primera línea de manejo para la dermatitis atópica, mientras que los inhibidores de la Janus Kinasa (JAK) son considerados únicamente en fallo terapéutico del anticuerpo monoclonal, pues su uso es más frecuente en patologías de reumatología que en enfermedades de la piel. Objetivo: Establecer la costó-utilidad de Baricitinib y Upadacitinib comparado con Dupilumab en monoterapia en pacientes adultos con dermatitis atópica a moderada a severa en Colombia, desde la perspectiva del tercer pagador. Metodología: Se realizó́ un análisis de costo-utilidad basado en un modelo de decisiones de Márkov a partir de fuentes secundarias, con revisión de la literatura. Teniendo en cuenta los precios en Colombia del 2023, desde la perspectiva del tercer pagador. Resultados: Upadacitinib a dosis de 15 mg y 30 mg resulto ser costo–útil para el tratamiento de la dermatitis atópica, respecto al tratamiento estándar Dupilumab Discusión: El Upadacitinib, aunque no es la primera línea de tratamiento para la dermatitis atópica en Colombia, según el presente estudio resultó ser más efectiva y económica para esta patología. |
| publishDate |
2023 |
| dc.date.accessioned.none.fl_str_mv |
2023-12-05T12:09:28Z |
| dc.date.available.none.fl_str_mv |
2023-12-05T12:09:28Z |
| dc.date.created.none.fl_str_mv |
2023-11-28 |
| dc.type.none.fl_str_mv |
bachelorThesis |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_7a1f |
| dc.type.document.none.fl_str_mv |
Trabajo de grado |
| dc.type.spa.none.fl_str_mv |
Trabajo de grado |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.48713/10336_41836 |
| dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/41836 |
| url |
https://doi.org/10.48713/10336_41836 https://repository.urosario.edu.co/handle/10336/41836 |
| dc.language.iso.none.fl_str_mv |
spa |
| language |
spa |
| dc.rights.*.fl_str_mv |
Attribution-NoDerivatives 4.0 International |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.acceso.none.fl_str_mv |
Abierto (Texto Completo) |
| dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nd/4.0/ |
| rights_invalid_str_mv |
Attribution-NoDerivatives 4.0 International Abierto (Texto Completo) http://creativecommons.org/licenses/by-nd/4.0/ http://purl.org/coar/access_right/c_abf2 |
| dc.format.extent.none.fl_str_mv |
67 pp |
| dc.format.mimetype.none.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
Universidad del Rosario |
| dc.publisher.department.spa.fl_str_mv |
Escuela de Medicina y Ciencias de la Salud |
| dc.publisher.program.spa.fl_str_mv |
Maestría en Epidemiología |
| institution |
Universidad del Rosario |
| dc.source.bibliographicCitation.none.fl_str_mv |
Beck, J. Robert; Pauker, Stephen G. (1983) The Markov Process in Medical Prognosis. En: Medical Decision Making. Vol. 3; No. 4; pp. 419 - 458; Disponible en: 10.1177/0272989X8300300403. FDA U.S. food and drugs (2023) Highlight of prescribing information. Disponible en: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program. Restrepo, Catalina; Escobar Valencia, Cristina; María, Ana; Giraldo, Mejía; Arango, Sindy Tamayo; Iván, Héctor; García, García; Lugo Agudelo, Luz Helena; Mesa, Gloria Sanclemente; Instrumentos de evaluación de la calidad de vida en dermatología. En: IATREIA. Vol. 26; No. 4; pp. 467 - 475; Finlay, A Y; Khan, G K (1994) Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. En: Clinical and Experimental Dermatology. Vol. 19; pp. 210 - 216; Disponible en: https://academic.oup.com/ced/article/19/3/210/6629483. Simpson, Eric; Bissonnette, Robert; Eichenfield, Lawrence F.; Guttman-Yassky, Emma; King, Brett; Silverberg, Jonathan I.; Beck, Lisa A.; Bieber, Thomas; Reich, Kristian; Kabashima, Kenji; Seyger, Marieke; Siegfried, Elaine; Stingl, Georg; Feldman, Steven R.; Menter, Alan; van de Kerkhof, Peter; Yosipovitch, Gil; Paul, Carle; Martel, Philippe; Dubost-Brama, Ariane; Armstrong, John; Chavda, Rajeev; Frey, Steve; Joubert, Yolandi; Milutinovic, Marina; Parneix, Anne; Teixeira, Henrique D.; Lin, Chen Yen; Sun, Luna; Klekotka, Paul; Nickoloff, Brian; Dutronc, Yves; Mallbris, Lotus; Janes, Jonathan M.; DeLozier, Amy M.; Nunes, Fabio P.; Paller, Amy S. (2020) The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. En: Journal of the American Academy of Dermatology. Vol. 83; No. 3; pp. 839 - 846; Mosby Inc.; Disponible en: 10.1016/j.jaad.2020.04.104. Hartmut Beck a, ⇑, Michael Härter a, Bastian Haß b, Carsten Schmeck a, Lars Baerfacker a (2022) Small molecules and their impact in drug discovery: A perspective on the occasion of the 125th anniversary of the Bayer Chemical Research Laboratory. Disponible en: https://doi.org/10.1016/j.drudis.2022.02.015This. Tiz, Davide Benedetto; Bagnoli, Luana; Rosati, Ornelio; Marini, Francesca; Santi, Claudio; Sancineto, Luca (2022) FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis. En: Pharmaceutics. Vol. 14; No. 11; MDPI; Disponible en: 10.3390/pharmaceutics14112538. Zarate, Víctor (2010) Evaluaciones económicas en salud: Conceptos básicos y clasificación. En: Rev Med Chile. Vol. 138; No. 2; pp. 93 - 97; Schappert, Susan M; Burt, Catharine W (2006) Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001-02. En: Vital and health statistics. Series 13, Data from the National Health Survey. No. 159; pp. 1 - 66; Instituto Nacional de Vigilancia a Medicamentos y alimentos (2021) Sala especializada de medicamentos. En: INVIMA. FDA U.S. Foods and drugs; Highlight of prescribing information. Disponible en: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program. Instituo Nacional de Vigilancia a Medicamentos y Alimentos; https://consultaregistro.invima.gov.co/Consultas/consultas/consreg_encabcum.jsp. Narla, Shanthi; Hsu, Derek Y.; Thyssen, Jacob P.; Silverberg, Jonathan I. (2017) Inpatient Financial Burden of Atopic Dermatitis in the United States. En: Journal of Investigative Dermatology. Vol. 137; No. 7; pp. 1461 - 1467; Elsevier B.V.; Disponible en: 10.1016/j.jid.2017.02.975. Davison, Niall J.; Thompson, Alexander J.; Turner, Alexander J.; Longworth, Louise; McElhone, Kathleen; Griffiths, Christopher E.M.; Payne, Katherine (2018) Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis. En: Value in Health. Vol. 21; No. 8; pp. 1010 - 1018; Elsevier Ltd; Disponible en: 10.1016/j.jval.2017.10.024. Cuervo, Miguel Mateo; Sanclemente, Gloria; Barrera, Lina Marcela (2021) Clinical and sociodemographic features and quality of life in patients with atopic dermatitis who attended dermatology teaching clinics in Medellm, Antioquia and its metropolitan area. En: Biomedica. Vol. 41; No. 4; pp. 1 - 38; Instituto Nacional de Salud; Disponible en: 10.7705/BIOMEDICA.5978. Drucker, Aaron M.; Qureshi, Abrar A.; Amand, Caroline; Villeneuve, Sara; Gadkari, Abhijit; Chao, Jingdong; Kuznik, Andreas; Bégo-Le-Bagousse, Gaëlle; Eckert, Laurent (2018) Health Care Resource Utilization and Costs Among Adults with Atopic Dermatitis in the United States: A Claims-Based Analysis. En: The Journal of Allergy and Clinical Immunology: In Practice. Vol. 6; No. 4; pp. 1342 - 1348; Disponible en: 10.1016/j.jaip.2017.10.024. dane (2023) https://www.dane.gov.co/index.php/estadisticas-por-tema/cuentas-nacionales/cuentas-nacionales-trimestrales/pib-informacion-tecnica. Blauvelt, Andrew; Teixeira, Henrique D; Simpson, Eric L; Costanzo, Antonio; De Bruin-Weller, Marjolein; Barbarot, Sebastien; Prajapati, Vimal H; Lio, Peter; Hu, Xiaofei; Wu, Tianshuang; Liu, John; Ladizinski, Barry; Chu, Alvina D; Eyerich, Kilian (2021) Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. En: JAMA dermatology. Vol. 157; No. 9; pp. 1047 - 1055; Disponible en: 10.1001/jamadermatol.2021.3023. de Bruin-Weller, Marjolein S; Serra-Baldrich, Esther; Barbarot, Sebastien; Grond, Susanne; Schuster, Christopher; Petto, Helmut; Capron, Jean-Philippe; Raibouaa, Afaf; Werfel, Thomas (2022) Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis. En: Dermatology and therapy. Vol. 12; No. 6; pp. 1481 - 1491; Disponible en: 10.1007/s13555-022-00734-w. Liu, Bo; Song, Xiaoting; Liao, Shuanglu; Luan, Tingting; Zhao, Zuotao (2023) Comparison of Efficacy of Baricitinib and Dupilumab in the Treatment of Chinese Moderate-To-Severe Atopic Dermatitis: A Retrospective Study. En: International Archives of Allergy and Immunology. pp. 1 - 9; Disponible en: 10.1159/000530394. Mar Javier, Antoñanzas Fernando, Pradas Roberto, Arrospide Arantzazu (2010) Los modelos de Markov probabilísticos en la evaluación económica de tecnologías sanitarias: una guía práctica. En: Gac Sanit [Internet]. Deleuran, Mette; Thaçi, Diamant; Beck, Lisa A; de Bruin-Weller, Marjolein; Blauvelt, Andrew; Forman, Seth; Bissonnette, Robert; Reich, Kristian; Soong, Weily; Hussain, Iftikhar; Foley, Peter; Hide, Michihiro; Bouaziz, Jean-David; Gelfand, Joel M; Sher, Lawrence; Schuttelaar, Marie L A; Wang, Chen; Chen, Zhen; Akinlade, Bolanle; Gadkari, Abhijit; Eckert, Laurent; Davis, John D; Rajadhyaksha, Manoj; Staudinger, Heribert; Graham, Neil M H; Pirozzi, Gianluca; Ardeleanu, Marius (2020) Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. En: Journal of the American Academy of Dermatology. Vol. 82; No. 2; pp. 377 - 388; Disponible en: 10.1016/j.jaad.2019.07.074. Simpson, Eric L; Papp, Kim A; Blauvelt, Andrew; Chu, Chia-Yu; Hong, H Chih-Ho; Katoh, Norito; Calimlim, Brian M; Thyssen, Jacob P; Chiou, Albert S; Bissonnette, Robert; Stein Gold, Linda F; Wegzyn, Colleen; Hu, Xiaofei; Liu, Meng; Liu, John; Tenorio, Allan R; Chu, Alvina D; Guttman-Yassky, Emma (2022) Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials. En: JAMA dermatology. Vol. 158; No. 4; pp. 404 - 413; Disponible en: 10.1001/jamadermatol.2022.0029. Silverberg, Jonathan I; Simpson, Eric L; Wollenberg, Andreas; Bissonnette, Robert; Kabashima, Kenji; DeLozier, Amy M; Sun, Luna; Cardillo, Tracy; Nunes, Fabio P; Reich, Kristian (2021) Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials. En: JAMA dermatology. Vol. 157; No. 6; pp. 691 - 699; Disponible en: 10.1001/jamadermatol.2021.1273. Simpson, Eric L.; Bieber, Thomas; Guttman-Yassky, Emma; Beck, Lisa A.; Blauvelt, Andrew; Cork, Michael J.; Silverberg, Jonathan I.; Deleuran, Mette; Kataoka, Yoko; Lacour, Jean-Philippe; Kingo, Külli; Worm, Margitta; Poulin, Yves; Wollenberg, Andreas; Soo, Yuhwen; Graham, Neil M.H.; Pirozzi, Gianluca; Akinlade, Bolanle; Staudinger, Heribert; Mastey, Vera; Eckert, Laurent; Gadkari, Abhijit; Stahl, Neil; Yancopoulos, George D.; Ardeleanu, Marius (2016) Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. En: New England Journal of Medicine. Vol. 375; No. 24; pp. 2335 - 2348; Disponible en: 10.1056/NEJMoa1610020. Simpson, E L; Lacour, J-P; Spelman, L; Galimberti, R; Eichenfield, L F; Bissonnette, R; King, B A; Thyssen, J P; Silverberg, J I; Bieber, T; Kabashima, K; Tsunemi, Y; Costanzo, A; Guttman-Yassky, E; Beck, L A; Janes, J M; DeLozier, A M; Gamalo, M; Brinker, D R; Cardillo, T; Nunes, F P; Paller, A S; Wollenberg, A; Reich, K (2020) Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. En: The British journal of dermatology. Vol. 183; No. 2; pp. 242 - 255; Disponible en: 10.1111/bjd.18898. Muñoz-Cerón, Joe Fernando; Rueda-Sánchez, Mauricio; Pradilla-Vesga, Oscar Enrique; Volcy, Michel; Hernández, Natalia; Ramírez, Sergio Francisco; Sobrino, Fidel; Uribe, Bernardo; Guerra, Carolina; Jiménez, Juan Diego; Ramos, Marta Liliana; Pradilla, Gustavo; Martínez, José David; Torres, Cesar Daniel; Torres, Gabriel (2020) Guideline on the preventive treatment of chronic migraine, chronic tension type headache, hemicrania continua and new daily persistent headache on behalf of the Colombian Association of Neurology. En: Acta Neurológica Colombiana. Vol. 36; No. 3; pp. 150 - 167; Disponible en: 10.22379/24224022300. Silverberg, Jonathan I. (2017) Public Health Burden and Epidemiology of Atopic Dermatitis. En: Dermatologic Clinics. Vol. 35; No. 3; pp. 283 - 289; W.B. Saunders; Disponible en: 10.1016/j.det.2017.02.002. Narla, Shanthi; Hsu, Derek Y.; Thyssen, Jacob P.; Silverberg, Jonathan I. (2017) Inpatient Financial Burden of Atopic Dermatitis in the United States. En: Journal of Investigative Dermatology. Vol. 137; No. 7; pp. 1461 - 1467; Elsevier B.V.; Disponible en: 10.1016/j.jid.2017.02.975. Guttman-Yassky, Emma; Teixeira, Henrique D.; Simpson, Eric L.; Papp, Kim A.; Pangan, Aileen L.; Blauvelt, Andrew; Thaçi, Diamant; Chu, Chia Yu; Hong, H. Chih ho; Katoh, Norito; Paller, Amy S.; Calimlim, Brian; Gu, Yihua; Hu, Xiaofei; Liu, Meng; Yang, Yang; Liu, John; Tenorio, Allan R.; Chu, Alvina D.; Irvine, Alan D. (2021) Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. En: The Lancet. Vol. 397; No. 10290; pp. 2151 - 2168; Elsevier B.V.; Disponible en: 10.1016/S0140-6736(21)00588-2. Reich, Kristian; Teixeira, Henrique D.; de Bruin-Weller, Marjolein; Bieber, Thomas; Soong, Weily; Kabashima, Kenji; Werfel, Thomas; Zeng, Jiewei; Huang, Xiaohong; Hu, Xiaofei; Hendrickson, Barbara A.; Ladizinski, Barry; Chu, Alvina D.; Silverberg, Jonathan I. (2021) Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. En: The Lancet. Vol. 397; No. 10290; pp. 2169 - 2181; Elsevier B.V.; Disponible en: 10.1016/S0140-6736(21)00589-4. Birdi, G; Cooke, R; Knibb, R C; Psychology, Gurkiran Birdi; Title: Impact of atopic dermatitis on quality of life in adults: A systematic review and meta-analysis. Agencia española de medicamentos y productos sanitarios (2023) Ficha técnica rinvoq 15. Disponible en: https://cima.aemps.es/cima/dochtml/ft/1191404001/FT_1191404001.html. Hanifin, Jon M.; Baghoomian, Wenelia; Grinich, Erin; Leshem, Yael A.; Jacobson, Michael; Simpson, Eric Lawrence (2022) The Eczema Area and Severity Index—A Practical Guide. En: Dermatitis. Vol. 33; No. 3; pp. 187 - 192; Disponible en: 10.1097/DER.0000000000000895. Kunz, B.; Oranje, A.P.; Labrèze, L.; Stalder, J.-F.; Ring, J.; Taïeb, A. (1997) Clinical Validation and Guidelines for the SCORAD Index: Consensus Report of the European Task Force on Atopic Dermatitis. En: Dermatology. Vol. 195; No. 1; pp. 10 - 19; Disponible en: 10.1159/000245677. Ortiz de Frutos, F.J.; Torrelo, A.; de Lucas, R.; González, M.A.; Alomar, A.; Vera, Á.; Ros, S.; Mora, A.M.; Cuervo, J. (2014) Dermatitis atópica desde la perspectiva del paciente: desencadenantes, cumplimiento de las recomendaciones médicas y control de la enfermedad. Estudio DATOP. En: Actas Dermo-Sifiliográficas. Vol. 105; No. 5; pp. 487 - 496; Elsevier BV; Disponible en: 10.1016/j.ad.2014.01.004. M Hanifin, the J; Thurston, M; Omoto, M; Cherill, R; Tofte, S J; Graeber, M (2001) EXPERIMENTAL DERMATOLOGY The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis The eczema area and severity index (EASI): assess-ment of reliability in atopic dermatitis the EASI Evaluator Group. En: Exp Dermatol. Vol. 10; pp. 11 - 18; C Munksgaard; Dennis, Rodolfo J.; Caraballo, Luis; García, Elizabeth; Rojas, María X.; Rondon, Martín A.; Pérez, Adriana; Aristizabal, Gustavo; Peñaranda, Augusto; Barragan, Ana M.; Ahumada, Velky; Jimenez, Silvia (2012) Prevalence of asthma and other allergic conditions in Colombia 2009-2010: a cross-sectional study. En: BMC Pulmonary Medicine. Vol. 12; Disponible en: 10.1186/1471-2466-12-17. Arturo Aviña Fierro, Jorge; Castañeda Gaytán, Daniel (2006) Núm. 2 • Mayo-Agosto. Vol. 15; pp. 50 - 56; Mortz, C. G.; Andersen, K. E.; Dellgren, C.; Barington, T.; Bindslev-Jensen, C. (2015) Atopic dermatitis from adolescence to adulthood in the TOACS cohort: Prevalence, persistence and comorbidities. En: Allergy: European Journal of Allergy and Clinical Immunology. Vol. 70; No. 7; pp. 836 - 845; Blackwell Publishing Ltd; Disponible en: 10.1111/all.12619. Barbarot, S.; Aubert, H.; Bernier, C.; Stalder, J.-F. (2016) Dermatitis atópica. En: EMC. Vol. 50; No. 4; pp. 1 - 22; Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1761289616808924. Disponible en: 10.1016/S1761-2896(16)80892-4. Eichenfield, Lawrence F.; Ellis, Charles N.; Mancini, Anthony J.; Paller, Amy S.; Simpson, Eric L. (2012) Atopic Dermatitis: Epidemiology and Pathogenesis Update. En: Seminars in Cutaneous Medicine and Surgery. Vol. 31; No. 3 SUPPL.; Disponible en: 10.1016/j.sder.2012.07.002. Cork, Michael J.; Eckert, Laurent; Simpson, Eric L.; Armstrong, April; Barbarot, Sébastien; Puig, Luis; Girolomoni, Giampiero; de Bruin-Weller, Marjolein; Wollenberg, Andreas; Kataoka, Yoko; Remitz, Anita; Beissert, Stefan; Mastey, Vera; Ardeleanu, Marius; Chen, Zhen; Gadkari, Abhijit; Chao, Jingdong (2020) Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. En: Journal of Dermatological Treatment. Vol. 31; No. 6; pp. 606 - 614; Taylor & Francis; Disponible en: https://doi.org/10.1080/09546634.2019.1612836. Disponible en: 10.1080/09546634.2019.1612836. JH, Sundjaja; Shrestha, R; Krishan, K (2022) StatPearls. Disponible en: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=32809534&site=eds-live. Sanclemente, G.; Burgos, C.; Nova, J.; Hernández, F.; González, C.; Reyes, M.I.; Córdoba, N.; Arèc)valo, Á.; Melèc)ndez, E.; Colmenares, J.; Ariza, S.; Hernández, G. (2017) The impact of skin diseases on quality of life: A multicenter study. En: Actas Dermo-Sifiliográficas (English Edition). Vol. 108; No. 3; pp. 244 - 252; Disponible en: 10.1016/j.adengl.2016.11.019. Drucker, Aaron M.; Morra, Deanna E.; Prieto-Merino, David; Ellis, Alexandra G.; Yiu, Zenas Z. N.; Rochwerg, Bram; Di Giorgio, Sonya; Arents, Bernd W. M.; Burton, Tim; Spuls, Phyllis I.; Schmitt, Jochen; Flohr, Carsten (2022) Systemic Immunomodulatory Treatments for Atopic Dermatitis. En: JAMA Dermatology. pp. 1 - 10; Disponible en: 10.1001/jamadermatol.2022.0455. Thaçi, Diamant; L. Simpson, Eric; Deleuran, Mette; Kataoka, Yoko; Chen, Zhen; Gadkari, Abhijit; Eckert, Laurent; Akinlade, Bolanle; Graham, Neil M.H.; Pirozzi, Gianluca; Ardeleanu, Marius (2019) Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). En: Journal of Dermatological Science. Vol. 94; No. 2; pp. 266 - 275; Japanese Society for Investigative Dermatology; Disponible en: https://doi.org/10.1016/j.jdermsci.2019.02.002. Disponible en: 10.1016/j.jdermsci.2019.02.002. Silverberg, Jonathan I.; Rubini, Norma P.M.; Pires, Mario C.; Rossi, Ana B.; Zhang, Annie; Chen, Zhen; Levit, Noah A.; Chao, Jingdong; Shumel, Brad; Bégo-Le Bagousse, Gaëlle (2022) Dupilumab Treatment Reduces Hospitalizations in Adults with Moderate-to-Severe Atopic Dermatitis. En: Journal of Allergy and Clinical Immunology: In Practice. Vol. 10; No. 5; pp. 1279 - 1285.e1; The Authors; Disponible en: https://doi.org/10.1016/j.jaip.2021.11.034. Disponible en: 10.1016/j.jaip.2021.11.034. Heinz, Katja C.; Willems, Damon; Hiligsmann, Mickaël (2022) Economic evaluation of a JAK inhibitor compared to a monoclonal antibody for treatment of moderate-to-severe atopic dermatitis from a UK perspective. En: Journal of Medical Economics. Vol. 25; No. 1; pp. 491 - 502; Taylor & Francis; Disponible en: https://doi.org/10.1080/13696998.2022.2059220. Disponible en: 10.1080/13696998.2022.2059220. Talamonti, Marina; Galluzzo, Marco; Silvaggio, Dionisio; Lombardo, Paolo; Tartaglia, Chiara; Bianchi, Luca (2021) Quality of life and psychological impact in patients with atopic dermatitis. En: Journal of Clinical Medicine. Vol. 10; No. 6; pp. 1 - 9; Disponible en: 10.3390/jcm10061298. Tsai, Hou Ren; Lu, Jing Wun; Chen, Li Yu; Chen, Tai Li (2021) Application of janus kinase inhibitors in atopic dermatitis: An updated systematic review and meta-analysis of clinical trials. En: Journal of Personalized Medicine. Vol. 11; No. 4; Disponible en: 10.3390/jpm11040279. Mortz, C. G.; Andersen, K. E.; Dellgren, C.; Barington, T.; Bindslev-Jensen, C. (2015) Atopic dermatitis from adolescence to adulthood in the TOACS cohort: Prevalence, persistence and comorbidities. En: Allergy: European Journal of Allergy and Clinical Immunology. Vol. 70; No. 7; pp. 836 - 845; Disponible en: 10.1111/all.12619. Hanifin, J. M.; Thurston, M.; Omoto, M.; Cherill, R.; Tofte, S. J.; Graeber, M. (2001) The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis. En: Experimental Dermatology. Vol. 10; No. 1; pp. 11 - 18; Disponible en: 10.1034/j.1600-0625.2001.100102.x. Wollenberg, A.; Christen-Zäch, S.; Taieb, A.; Paul, C.; Thyssen, J. P.; de Bruin-Weller, M.; Vestergaard, C.; Seneschal, J.; Werfel, T.; Cork, M. J.; Kunz, B.; Fölster-Holst, R.; Trzeciak, M.; Darsow, U.; Szalai, Z.; Deleuran, M.; von Kobyletzki, L.; Barbarot, S.; Heratizadeh, A.; Gieler, U.; Hijnen, D. J.; Weidinger, S.; De Raeve, L.; Svensson; Simon, D.; Stalder, J. F.; Ring, J. (2020) ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. En: Journal of the European Academy of Dermatology and Venereology. Vol. 34; No. 12; pp. 2717 - 2744; Disponible en: 10.1111/jdv.16892. Colombiana, Asociación; Dermatología, De; Dermatológica, Cirugía (2018) Asociación Colombiana de Dermatología y Cirugía Dermatológica e Instituto de Evaluación Tecnológica en Salud (IETS). Guía de práctica clínica para el diagnóstico y tratamiento de la dermatitis atópica en Colombia. pp. 250 - 250; Disponible en: https://revistasocolderma.org/sites/default/files/guia_de_practica_clinica_dermatitis_atopica_oct_2018.pdf. Reich, Kristian; Teixeira, Henrique D.; de Bruin-Weller, Marjolein; Bieber, Thomas; Soong, Weily; Kabashima, Kenji; Werfel, Thomas; Zeng, Jiewei; Huang, Xiaohong; Hu, Xiaofei; Hendrickson, Barbara A.; Ladizinski, Barry; Chu, Alvina D.; Silverberg, Jonathan I. (2021) Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. En: The Lancet. Vol. 397; No. 10290; pp. 2169 - 2181; Elsevier Ltd; Disponible en: http://dx.doi.org/10.1016/S0140-6736(21)00589-4. Disponible en: 10.1016/S0140-6736(21)00589-4. Guttman-Yassky, Emma; Teixeira, Henrique D.; Simpson, Eric L.; Papp, Kim A.; Pangan, Aileen L.; Blauvelt, Andrew; Thaçi, Diamant; Chu, Chia Yu; Hong, H. Chih ho; Katoh, Norito; Paller, Amy S.; Calimlim, Brian; Gu, Yihua; Hu, Xiaofei; Liu, Meng; Yang, Yang; Liu, John; Tenorio, Allan R.; Chu, Alvina D.; Irvine, Alan D. (2021) Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. En: The Lancet. Vol. 397; No. 10290; pp. 2151 - 2168; Disponible en: 10.1016/S0140-6736(21)00588-2. |
| dc.source.instname.none.fl_str_mv |
instname:Universidad del Rosario |
| dc.source.reponame.none.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
| bitstream.url.fl_str_mv |
https://repository.urosario.edu.co/bitstreams/425f6bd1-65de-4f6b-bc91-525a457bceb4/download https://repository.urosario.edu.co/bitstreams/5c1b9d00-c8b7-40d5-8303-f5b79efec64a/download https://repository.urosario.edu.co/bitstreams/15257564-cec7-4d2d-a32c-06977260e04f/download https://repository.urosario.edu.co/bitstreams/267f4133-3629-412c-853c-2731d19604c6/download https://repository.urosario.edu.co/bitstreams/19559b34-3503-4478-87cb-1a80e19de65e/download https://repository.urosario.edu.co/bitstreams/4c5afa66-00ff-442f-aa49-00927a425689/download |
| bitstream.checksum.fl_str_mv |
b08d0b19b3914fc3aaa0efa7490edf5d bb2fd2a595f116ef6dea8e54d11d4530 b2825df9f458e9d5d96ee8b7cd74fde6 5310bb89a00d5ead086944535cc857c4 ce129625f825e2285d9b4b0139cc480f e41e1e7b670048ceb397f1756f760086 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio institucional EdocUR |
| repository.mail.fl_str_mv |
edocur@urosario.edu.co |
| _version_ |
1808391078656606208 |
| spelling |
Bareño Silva, José7c3e2a4d-af6b-4a05-bf76-e786f91ac575-1Godoy Collazos, Ana MaríaOspina Bocanegra, Fabio EnriqueMagíster en EpidemiologíaMaestríaPart time8517fe25-4f3f-4650-b0c4-17e6712c0792-1977de9e3-b4bd-421e-8580-dcfbe2aa14f5-12023-12-05T12:09:28Z2023-12-05T12:09:28Z2023-11-28La dermatitis atópica (DA) es una enfermedad de la piel con un alto impacto social y económico tanto para el sistema de salud como para el paciente, en Colombia las moléculas de Dupilumab, Upadacitinib y Baricitinib tienen aprobación por el Invima para su uso en casos de enfermedad moderada a severa. Dupilumab continúa siendo la primera línea de manejo para la dermatitis atópica, mientras que los inhibidores de la Janus Kinasa (JAK) son considerados únicamente en fallo terapéutico del anticuerpo monoclonal, pues su uso es más frecuente en patologías de reumatología que en enfermedades de la piel. Objetivo: Establecer la costó-utilidad de Baricitinib y Upadacitinib comparado con Dupilumab en monoterapia en pacientes adultos con dermatitis atópica a moderada a severa en Colombia, desde la perspectiva del tercer pagador. Metodología: Se realizó́ un análisis de costo-utilidad basado en un modelo de decisiones de Márkov a partir de fuentes secundarias, con revisión de la literatura. Teniendo en cuenta los precios en Colombia del 2023, desde la perspectiva del tercer pagador. Resultados: Upadacitinib a dosis de 15 mg y 30 mg resulto ser costo–útil para el tratamiento de la dermatitis atópica, respecto al tratamiento estándar Dupilumab Discusión: El Upadacitinib, aunque no es la primera línea de tratamiento para la dermatitis atópica en Colombia, según el presente estudio resultó ser más efectiva y económica para esta patología.Atopic dermatitis (AD) is a skin disease with a high social and economic impact on the health system and the patient. In Colombia, the Dupilumab, Upadacitinib, and Baricitinib molecules are approved by Invima for their use in cases of moderate to severe disease. Dupilumab continues to be the first line of management for atopic dermatitis. At the same time, Janus Kinase (JAK) inhibitors are considered only in the therapeutic failure of the monoclonal antibody, since their use is more frequent in rheumatology pathologies than in skin diseases. Objective: To establish the cost-utility of Baricitinib and Upadacitinib compared to Dupilumab in monotherapy in adult patients with moderate to severe atopic dermatitis in Colombia, from the perspective of the third payer. Methodology: A cost-utility analysis was carried out based on a Markov decision model from secondary sources, with a literature review, using the prices in Colombia in 2023, from the perspective of the third payer. Results: Upadacitinib at doses of 15 mg and 30 mg turned out to be cost-useful for the treatment of atopic dermatitis, compared to the standard treatment of Dupilumab. Discussion: Upadacitinib, although it is not the first line of treatment for atopic dermatitis in Colombia, according to the present study turned out to be more effective and economical for this pathology.67 ppapplication/pdfhttps://doi.org/10.48713/10336_41836 https://repository.urosario.edu.co/handle/10336/41836spaUniversidad del RosarioEscuela de Medicina y Ciencias de la SaludMaestría en EpidemiologíaAttribution-NoDerivatives 4.0 InternationalAbierto (Texto Completo)EL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.http://creativecommons.org/licenses/by-nd/4.0/http://purl.org/coar/access_right/c_abf2Beck, J. Robert; Pauker, Stephen G. (1983) The Markov Process in Medical Prognosis. En: Medical Decision Making. Vol. 3; No. 4; pp. 419 - 458; Disponible en: 10.1177/0272989X8300300403.FDA U.S. food and drugs (2023) Highlight of prescribing information. Disponible en: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program.Restrepo, Catalina; Escobar Valencia, Cristina; María, Ana; Giraldo, Mejía; Arango, Sindy Tamayo; Iván, Héctor; García, García; Lugo Agudelo, Luz Helena; Mesa, Gloria Sanclemente; Instrumentos de evaluación de la calidad de vida en dermatología. En: IATREIA. Vol. 26; No. 4; pp. 467 - 475;Finlay, A Y; Khan, G K (1994) Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. En: Clinical and Experimental Dermatology. Vol. 19; pp. 210 - 216; Disponible en: https://academic.oup.com/ced/article/19/3/210/6629483.Simpson, Eric; Bissonnette, Robert; Eichenfield, Lawrence F.; Guttman-Yassky, Emma; King, Brett; Silverberg, Jonathan I.; Beck, Lisa A.; Bieber, Thomas; Reich, Kristian; Kabashima, Kenji; Seyger, Marieke; Siegfried, Elaine; Stingl, Georg; Feldman, Steven R.; Menter, Alan; van de Kerkhof, Peter; Yosipovitch, Gil; Paul, Carle; Martel, Philippe; Dubost-Brama, Ariane; Armstrong, John; Chavda, Rajeev; Frey, Steve; Joubert, Yolandi; Milutinovic, Marina; Parneix, Anne; Teixeira, Henrique D.; Lin, Chen Yen; Sun, Luna; Klekotka, Paul; Nickoloff, Brian; Dutronc, Yves; Mallbris, Lotus; Janes, Jonathan M.; DeLozier, Amy M.; Nunes, Fabio P.; Paller, Amy S. (2020) The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. En: Journal of the American Academy of Dermatology. Vol. 83; No. 3; pp. 839 - 846; Mosby Inc.; Disponible en: 10.1016/j.jaad.2020.04.104.Hartmut Beck a, ⇑, Michael Härter a, Bastian Haß b, Carsten Schmeck a, Lars Baerfacker a (2022) Small molecules and their impact in drug discovery: A perspective on the occasion of the 125th anniversary of the Bayer Chemical Research Laboratory. Disponible en: https://doi.org/10.1016/j.drudis.2022.02.015This.Tiz, Davide Benedetto; Bagnoli, Luana; Rosati, Ornelio; Marini, Francesca; Santi, Claudio; Sancineto, Luca (2022) FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis. En: Pharmaceutics. Vol. 14; No. 11; MDPI; Disponible en: 10.3390/pharmaceutics14112538.Zarate, Víctor (2010) Evaluaciones económicas en salud: Conceptos básicos y clasificación. En: Rev Med Chile. Vol. 138; No. 2; pp. 93 - 97;Schappert, Susan M; Burt, Catharine W (2006) Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001-02. En: Vital and health statistics. Series 13, Data from the National Health Survey. No. 159; pp. 1 - 66;Instituto Nacional de Vigilancia a Medicamentos y alimentos (2021) Sala especializada de medicamentos. En: INVIMA.FDA U.S. Foods and drugs; Highlight of prescribing information. Disponible en: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program.Instituo Nacional de Vigilancia a Medicamentos y Alimentos; https://consultaregistro.invima.gov.co/Consultas/consultas/consreg_encabcum.jsp. Narla, Shanthi; Hsu, Derek Y.; Thyssen, Jacob P.; Silverberg, Jonathan I. (2017) Inpatient Financial Burden of Atopic Dermatitis in the United States. En: Journal of Investigative Dermatology. Vol. 137; No. 7; pp. 1461 - 1467; Elsevier B.V.; Disponible en: 10.1016/j.jid.2017.02.975.Davison, Niall J.; Thompson, Alexander J.; Turner, Alexander J.; Longworth, Louise; McElhone, Kathleen; Griffiths, Christopher E.M.; Payne, Katherine (2018) Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis. En: Value in Health. Vol. 21; No. 8; pp. 1010 - 1018; Elsevier Ltd; Disponible en: 10.1016/j.jval.2017.10.024.Cuervo, Miguel Mateo; Sanclemente, Gloria; Barrera, Lina Marcela (2021) Clinical and sociodemographic features and quality of life in patients with atopic dermatitis who attended dermatology teaching clinics in Medellm, Antioquia and its metropolitan area. En: Biomedica. Vol. 41; No. 4; pp. 1 - 38; Instituto Nacional de Salud; Disponible en: 10.7705/BIOMEDICA.5978.Drucker, Aaron M.; Qureshi, Abrar A.; Amand, Caroline; Villeneuve, Sara; Gadkari, Abhijit; Chao, Jingdong; Kuznik, Andreas; Bégo-Le-Bagousse, Gaëlle; Eckert, Laurent (2018) Health Care Resource Utilization and Costs Among Adults with Atopic Dermatitis in the United States: A Claims-Based Analysis. En: The Journal of Allergy and Clinical Immunology: In Practice. Vol. 6; No. 4; pp. 1342 - 1348; Disponible en: 10.1016/j.jaip.2017.10.024.dane (2023) https://www.dane.gov.co/index.php/estadisticas-por-tema/cuentas-nacionales/cuentas-nacionales-trimestrales/pib-informacion-tecnica. Blauvelt, Andrew; Teixeira, Henrique D; Simpson, Eric L; Costanzo, Antonio; De Bruin-Weller, Marjolein; Barbarot, Sebastien; Prajapati, Vimal H; Lio, Peter; Hu, Xiaofei; Wu, Tianshuang; Liu, John; Ladizinski, Barry; Chu, Alvina D; Eyerich, Kilian (2021) Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. En: JAMA dermatology. Vol. 157; No. 9; pp. 1047 - 1055; Disponible en: 10.1001/jamadermatol.2021.3023.de Bruin-Weller, Marjolein S; Serra-Baldrich, Esther; Barbarot, Sebastien; Grond, Susanne; Schuster, Christopher; Petto, Helmut; Capron, Jean-Philippe; Raibouaa, Afaf; Werfel, Thomas (2022) Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis. En: Dermatology and therapy. Vol. 12; No. 6; pp. 1481 - 1491; Disponible en: 10.1007/s13555-022-00734-w.Liu, Bo; Song, Xiaoting; Liao, Shuanglu; Luan, Tingting; Zhao, Zuotao (2023) Comparison of Efficacy of Baricitinib and Dupilumab in the Treatment of Chinese Moderate-To-Severe Atopic Dermatitis: A Retrospective Study. En: International Archives of Allergy and Immunology. pp. 1 - 9; Disponible en: 10.1159/000530394.Mar Javier, Antoñanzas Fernando, Pradas Roberto, Arrospide Arantzazu (2010) Los modelos de Markov probabilísticos en la evaluación económica de tecnologías sanitarias: una guía práctica. En: Gac Sanit [Internet].Deleuran, Mette; Thaçi, Diamant; Beck, Lisa A; de Bruin-Weller, Marjolein; Blauvelt, Andrew; Forman, Seth; Bissonnette, Robert; Reich, Kristian; Soong, Weily; Hussain, Iftikhar; Foley, Peter; Hide, Michihiro; Bouaziz, Jean-David; Gelfand, Joel M; Sher, Lawrence; Schuttelaar, Marie L A; Wang, Chen; Chen, Zhen; Akinlade, Bolanle; Gadkari, Abhijit; Eckert, Laurent; Davis, John D; Rajadhyaksha, Manoj; Staudinger, Heribert; Graham, Neil M H; Pirozzi, Gianluca; Ardeleanu, Marius (2020) Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. En: Journal of the American Academy of Dermatology. Vol. 82; No. 2; pp. 377 - 388; Disponible en: 10.1016/j.jaad.2019.07.074.Simpson, Eric L; Papp, Kim A; Blauvelt, Andrew; Chu, Chia-Yu; Hong, H Chih-Ho; Katoh, Norito; Calimlim, Brian M; Thyssen, Jacob P; Chiou, Albert S; Bissonnette, Robert; Stein Gold, Linda F; Wegzyn, Colleen; Hu, Xiaofei; Liu, Meng; Liu, John; Tenorio, Allan R; Chu, Alvina D; Guttman-Yassky, Emma (2022) Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials. En: JAMA dermatology. Vol. 158; No. 4; pp. 404 - 413; Disponible en: 10.1001/jamadermatol.2022.0029.Silverberg, Jonathan I; Simpson, Eric L; Wollenberg, Andreas; Bissonnette, Robert; Kabashima, Kenji; DeLozier, Amy M; Sun, Luna; Cardillo, Tracy; Nunes, Fabio P; Reich, Kristian (2021) Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials. En: JAMA dermatology. Vol. 157; No. 6; pp. 691 - 699; Disponible en: 10.1001/jamadermatol.2021.1273.Simpson, Eric L.; Bieber, Thomas; Guttman-Yassky, Emma; Beck, Lisa A.; Blauvelt, Andrew; Cork, Michael J.; Silverberg, Jonathan I.; Deleuran, Mette; Kataoka, Yoko; Lacour, Jean-Philippe; Kingo, Külli; Worm, Margitta; Poulin, Yves; Wollenberg, Andreas; Soo, Yuhwen; Graham, Neil M.H.; Pirozzi, Gianluca; Akinlade, Bolanle; Staudinger, Heribert; Mastey, Vera; Eckert, Laurent; Gadkari, Abhijit; Stahl, Neil; Yancopoulos, George D.; Ardeleanu, Marius (2016) Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. En: New England Journal of Medicine. Vol. 375; No. 24; pp. 2335 - 2348; Disponible en: 10.1056/NEJMoa1610020.Simpson, E L; Lacour, J-P; Spelman, L; Galimberti, R; Eichenfield, L F; Bissonnette, R; King, B A; Thyssen, J P; Silverberg, J I; Bieber, T; Kabashima, K; Tsunemi, Y; Costanzo, A; Guttman-Yassky, E; Beck, L A; Janes, J M; DeLozier, A M; Gamalo, M; Brinker, D R; Cardillo, T; Nunes, F P; Paller, A S; Wollenberg, A; Reich, K (2020) Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. En: The British journal of dermatology. Vol. 183; No. 2; pp. 242 - 255; Disponible en: 10.1111/bjd.18898.Muñoz-Cerón, Joe Fernando; Rueda-Sánchez, Mauricio; Pradilla-Vesga, Oscar Enrique; Volcy, Michel; Hernández, Natalia; Ramírez, Sergio Francisco; Sobrino, Fidel; Uribe, Bernardo; Guerra, Carolina; Jiménez, Juan Diego; Ramos, Marta Liliana; Pradilla, Gustavo; Martínez, José David; Torres, Cesar Daniel; Torres, Gabriel (2020) Guideline on the preventive treatment of chronic migraine, chronic tension type headache, hemicrania continua and new daily persistent headache on behalf of the Colombian Association of Neurology. En: Acta Neurológica Colombiana. Vol. 36; No. 3; pp. 150 - 167; Disponible en: 10.22379/24224022300.Silverberg, Jonathan I. (2017) Public Health Burden and Epidemiology of Atopic Dermatitis. En: Dermatologic Clinics. Vol. 35; No. 3; pp. 283 - 289; W.B. Saunders; Disponible en: 10.1016/j.det.2017.02.002.Narla, Shanthi; Hsu, Derek Y.; Thyssen, Jacob P.; Silverberg, Jonathan I. (2017) Inpatient Financial Burden of Atopic Dermatitis in the United States. En: Journal of Investigative Dermatology. Vol. 137; No. 7; pp. 1461 - 1467; Elsevier B.V.; Disponible en: 10.1016/j.jid.2017.02.975.Guttman-Yassky, Emma; Teixeira, Henrique D.; Simpson, Eric L.; Papp, Kim A.; Pangan, Aileen L.; Blauvelt, Andrew; Thaçi, Diamant; Chu, Chia Yu; Hong, H. Chih ho; Katoh, Norito; Paller, Amy S.; Calimlim, Brian; Gu, Yihua; Hu, Xiaofei; Liu, Meng; Yang, Yang; Liu, John; Tenorio, Allan R.; Chu, Alvina D.; Irvine, Alan D. (2021) Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. En: The Lancet. Vol. 397; No. 10290; pp. 2151 - 2168; Elsevier B.V.; Disponible en: 10.1016/S0140-6736(21)00588-2.Reich, Kristian; Teixeira, Henrique D.; de Bruin-Weller, Marjolein; Bieber, Thomas; Soong, Weily; Kabashima, Kenji; Werfel, Thomas; Zeng, Jiewei; Huang, Xiaohong; Hu, Xiaofei; Hendrickson, Barbara A.; Ladizinski, Barry; Chu, Alvina D.; Silverberg, Jonathan I. (2021) Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. En: The Lancet. Vol. 397; No. 10290; pp. 2169 - 2181; Elsevier B.V.; Disponible en: 10.1016/S0140-6736(21)00589-4.Birdi, G; Cooke, R; Knibb, R C; Psychology, Gurkiran Birdi; Title: Impact of atopic dermatitis on quality of life in adults: A systematic review and meta-analysis. Agencia española de medicamentos y productos sanitarios (2023) Ficha técnica rinvoq 15. Disponible en: https://cima.aemps.es/cima/dochtml/ft/1191404001/FT_1191404001.html.Hanifin, Jon M.; Baghoomian, Wenelia; Grinich, Erin; Leshem, Yael A.; Jacobson, Michael; Simpson, Eric Lawrence (2022) The Eczema Area and Severity Index—A Practical Guide. En: Dermatitis. Vol. 33; No. 3; pp. 187 - 192; Disponible en: 10.1097/DER.0000000000000895.Kunz, B.; Oranje, A.P.; Labrèze, L.; Stalder, J.-F.; Ring, J.; Taïeb, A. (1997) Clinical Validation and Guidelines for the SCORAD Index: Consensus Report of the European Task Force on Atopic Dermatitis. En: Dermatology. Vol. 195; No. 1; pp. 10 - 19; Disponible en: 10.1159/000245677.Ortiz de Frutos, F.J.; Torrelo, A.; de Lucas, R.; González, M.A.; Alomar, A.; Vera, Á.; Ros, S.; Mora, A.M.; Cuervo, J. (2014) Dermatitis atópica desde la perspectiva del paciente: desencadenantes, cumplimiento de las recomendaciones médicas y control de la enfermedad. Estudio DATOP. En: Actas Dermo-Sifiliográficas. Vol. 105; No. 5; pp. 487 - 496; Elsevier BV; Disponible en: 10.1016/j.ad.2014.01.004.M Hanifin, the J; Thurston, M; Omoto, M; Cherill, R; Tofte, S J; Graeber, M (2001) EXPERIMENTAL DERMATOLOGY The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis The eczema area and severity index (EASI): assess-ment of reliability in atopic dermatitis the EASI Evaluator Group. En: Exp Dermatol. Vol. 10; pp. 11 - 18; C Munksgaard;Dennis, Rodolfo J.; Caraballo, Luis; García, Elizabeth; Rojas, María X.; Rondon, Martín A.; Pérez, Adriana; Aristizabal, Gustavo; Peñaranda, Augusto; Barragan, Ana M.; Ahumada, Velky; Jimenez, Silvia (2012) Prevalence of asthma and other allergic conditions in Colombia 2009-2010: a cross-sectional study. En: BMC Pulmonary Medicine. Vol. 12; Disponible en: 10.1186/1471-2466-12-17.Arturo Aviña Fierro, Jorge; Castañeda Gaytán, Daniel (2006) Núm. 2 • Mayo-Agosto. Vol. 15; pp. 50 - 56;Mortz, C. G.; Andersen, K. E.; Dellgren, C.; Barington, T.; Bindslev-Jensen, C. (2015) Atopic dermatitis from adolescence to adulthood in the TOACS cohort: Prevalence, persistence and comorbidities. En: Allergy: European Journal of Allergy and Clinical Immunology. Vol. 70; No. 7; pp. 836 - 845; Blackwell Publishing Ltd; Disponible en: 10.1111/all.12619.Barbarot, S.; Aubert, H.; Bernier, C.; Stalder, J.-F. (2016) Dermatitis atópica. En: EMC. Vol. 50; No. 4; pp. 1 - 22; Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1761289616808924. Disponible en: 10.1016/S1761-2896(16)80892-4.Eichenfield, Lawrence F.; Ellis, Charles N.; Mancini, Anthony J.; Paller, Amy S.; Simpson, Eric L. (2012) Atopic Dermatitis: Epidemiology and Pathogenesis Update. En: Seminars in Cutaneous Medicine and Surgery. Vol. 31; No. 3 SUPPL.; Disponible en: 10.1016/j.sder.2012.07.002.Cork, Michael J.; Eckert, Laurent; Simpson, Eric L.; Armstrong, April; Barbarot, Sébastien; Puig, Luis; Girolomoni, Giampiero; de Bruin-Weller, Marjolein; Wollenberg, Andreas; Kataoka, Yoko; Remitz, Anita; Beissert, Stefan; Mastey, Vera; Ardeleanu, Marius; Chen, Zhen; Gadkari, Abhijit; Chao, Jingdong (2020) Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. En: Journal of Dermatological Treatment. Vol. 31; No. 6; pp. 606 - 614; Taylor & Francis; Disponible en: https://doi.org/10.1080/09546634.2019.1612836. Disponible en: 10.1080/09546634.2019.1612836.JH, Sundjaja; Shrestha, R; Krishan, K (2022) StatPearls. Disponible en: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=32809534&site=eds-live.Sanclemente, G.; Burgos, C.; Nova, J.; Hernández, F.; González, C.; Reyes, M.I.; Córdoba, N.; Arèc)valo, Á.; Melèc)ndez, E.; Colmenares, J.; Ariza, S.; Hernández, G. (2017) The impact of skin diseases on quality of life: A multicenter study. En: Actas Dermo-Sifiliográficas (English Edition). Vol. 108; No. 3; pp. 244 - 252; Disponible en: 10.1016/j.adengl.2016.11.019.Drucker, Aaron M.; Morra, Deanna E.; Prieto-Merino, David; Ellis, Alexandra G.; Yiu, Zenas Z. N.; Rochwerg, Bram; Di Giorgio, Sonya; Arents, Bernd W. M.; Burton, Tim; Spuls, Phyllis I.; Schmitt, Jochen; Flohr, Carsten (2022) Systemic Immunomodulatory Treatments for Atopic Dermatitis. En: JAMA Dermatology. pp. 1 - 10; Disponible en: 10.1001/jamadermatol.2022.0455.Thaçi, Diamant; L. Simpson, Eric; Deleuran, Mette; Kataoka, Yoko; Chen, Zhen; Gadkari, Abhijit; Eckert, Laurent; Akinlade, Bolanle; Graham, Neil M.H.; Pirozzi, Gianluca; Ardeleanu, Marius (2019) Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). En: Journal of Dermatological Science. Vol. 94; No. 2; pp. 266 - 275; Japanese Society for Investigative Dermatology; Disponible en: https://doi.org/10.1016/j.jdermsci.2019.02.002. Disponible en: 10.1016/j.jdermsci.2019.02.002.Silverberg, Jonathan I.; Rubini, Norma P.M.; Pires, Mario C.; Rossi, Ana B.; Zhang, Annie; Chen, Zhen; Levit, Noah A.; Chao, Jingdong; Shumel, Brad; Bégo-Le Bagousse, Gaëlle (2022) Dupilumab Treatment Reduces Hospitalizations in Adults with Moderate-to-Severe Atopic Dermatitis. En: Journal of Allergy and Clinical Immunology: In Practice. Vol. 10; No. 5; pp. 1279 - 1285.e1; The Authors; Disponible en: https://doi.org/10.1016/j.jaip.2021.11.034. Disponible en: 10.1016/j.jaip.2021.11.034.Heinz, Katja C.; Willems, Damon; Hiligsmann, Mickaël (2022) Economic evaluation of a JAK inhibitor compared to a monoclonal antibody for treatment of moderate-to-severe atopic dermatitis from a UK perspective. En: Journal of Medical Economics. Vol. 25; No. 1; pp. 491 - 502; Taylor & Francis; Disponible en: https://doi.org/10.1080/13696998.2022.2059220. Disponible en: 10.1080/13696998.2022.2059220.Talamonti, Marina; Galluzzo, Marco; Silvaggio, Dionisio; Lombardo, Paolo; Tartaglia, Chiara; Bianchi, Luca (2021) Quality of life and psychological impact in patients with atopic dermatitis. En: Journal of Clinical Medicine. Vol. 10; No. 6; pp. 1 - 9; Disponible en: 10.3390/jcm10061298.Tsai, Hou Ren; Lu, Jing Wun; Chen, Li Yu; Chen, Tai Li (2021) Application of janus kinase inhibitors in atopic dermatitis: An updated systematic review and meta-analysis of clinical trials. En: Journal of Personalized Medicine. Vol. 11; No. 4; Disponible en: 10.3390/jpm11040279.Mortz, C. G.; Andersen, K. E.; Dellgren, C.; Barington, T.; Bindslev-Jensen, C. (2015) Atopic dermatitis from adolescence to adulthood in the TOACS cohort: Prevalence, persistence and comorbidities. En: Allergy: European Journal of Allergy and Clinical Immunology. Vol. 70; No. 7; pp. 836 - 845; Disponible en: 10.1111/all.12619.Hanifin, J. M.; Thurston, M.; Omoto, M.; Cherill, R.; Tofte, S. J.; Graeber, M. (2001) The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis. En: Experimental Dermatology. Vol. 10; No. 1; pp. 11 - 18; Disponible en: 10.1034/j.1600-0625.2001.100102.x.Wollenberg, A.; Christen-Zäch, S.; Taieb, A.; Paul, C.; Thyssen, J. P.; de Bruin-Weller, M.; Vestergaard, C.; Seneschal, J.; Werfel, T.; Cork, M. J.; Kunz, B.; Fölster-Holst, R.; Trzeciak, M.; Darsow, U.; Szalai, Z.; Deleuran, M.; von Kobyletzki, L.; Barbarot, S.; Heratizadeh, A.; Gieler, U.; Hijnen, D. J.; Weidinger, S.; De Raeve, L.; Svensson; Simon, D.; Stalder, J. F.; Ring, J. (2020) ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. En: Journal of the European Academy of Dermatology and Venereology. Vol. 34; No. 12; pp. 2717 - 2744; Disponible en: 10.1111/jdv.16892.Colombiana, Asociación; Dermatología, De; Dermatológica, Cirugía (2018) Asociación Colombiana de Dermatología y Cirugía Dermatológica e Instituto de Evaluación Tecnológica en Salud (IETS). Guía de práctica clínica para el diagnóstico y tratamiento de la dermatitis atópica en Colombia. pp. 250 - 250; Disponible en: https://revistasocolderma.org/sites/default/files/guia_de_practica_clinica_dermatitis_atopica_oct_2018.pdf.Reich, Kristian; Teixeira, Henrique D.; de Bruin-Weller, Marjolein; Bieber, Thomas; Soong, Weily; Kabashima, Kenji; Werfel, Thomas; Zeng, Jiewei; Huang, Xiaohong; Hu, Xiaofei; Hendrickson, Barbara A.; Ladizinski, Barry; Chu, Alvina D.; Silverberg, Jonathan I. (2021) Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. En: The Lancet. Vol. 397; No. 10290; pp. 2169 - 2181; Elsevier Ltd; Disponible en: http://dx.doi.org/10.1016/S0140-6736(21)00589-4. Disponible en: 10.1016/S0140-6736(21)00589-4.Guttman-Yassky, Emma; Teixeira, Henrique D.; Simpson, Eric L.; Papp, Kim A.; Pangan, Aileen L.; Blauvelt, Andrew; Thaçi, Diamant; Chu, Chia Yu; Hong, H. Chih ho; Katoh, Norito; Paller, Amy S.; Calimlim, Brian; Gu, Yihua; Hu, Xiaofei; Liu, Meng; Yang, Yang; Liu, John; Tenorio, Allan R.; Chu, Alvina D.; Irvine, Alan D. (2021) Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. En: The Lancet. Vol. 397; No. 10290; pp. 2151 - 2168; Disponible en: 10.1016/S0140-6736(21)00588-2.instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURDermatitis atópicaBiológicosIhibidores JAKCostosAnálisis de costosAtopic dermatitisBiologicsJAK inhibitorsCostCost analysisAnálisis de costo- utilidad de Baricitinib y Upadacitinib comparado con Dupilumab en monoterapia en pacientes adultos con dermatitis atópica moderada a severa en ColombiaCost-utility analysis of Baricitinib and Upadacitinib compared with Dupilumab monotherapy in adult patients with moderate to severe atopic dermatitis in ColombiabachelorThesisTrabajo de gradoTrabajo de gradohttp://purl.org/coar/resource_type/c_7a1fEscuela de Medicina y Ciencias de la SaludORIGINALAnalisis_de_costo_utilidad_baricitnib_Gody_Collazos_Ana_Maria.pdfAnalisis_de_costo_utilidad_baricitnib_Gody_Collazos_Ana_Maria.pdfapplication/pdf1542289https://repository.urosario.edu.co/bitstreams/425f6bd1-65de-4f6b-bc91-525a457bceb4/downloadb08d0b19b3914fc3aaa0efa7490edf5dMD51Analisis_de_costo_utilidad_baricitnib_Gody_Collazos_Ana_Maria.risAnalisis_de_costo_utilidad_baricitnib_Gody_Collazos_Ana_Maria.risapplication/x-research-info-systems112624https://repository.urosario.edu.co/bitstreams/5c1b9d00-c8b7-40d5-8303-f5b79efec64a/downloadbb2fd2a595f116ef6dea8e54d11d4530MD54LICENSElicense.txtlicense.txttext/plain1483https://repository.urosario.edu.co/bitstreams/15257564-cec7-4d2d-a32c-06977260e04f/downloadb2825df9f458e9d5d96ee8b7cd74fde6MD52CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8893https://repository.urosario.edu.co/bitstreams/267f4133-3629-412c-853c-2731d19604c6/download5310bb89a00d5ead086944535cc857c4MD53TEXTAnalisis_de_costo_utilidad_baricitnib_Gody_Collazos_Ana_Maria.pdf.txtAnalisis_de_costo_utilidad_baricitnib_Gody_Collazos_Ana_Maria.pdf.txtExtracted texttext/plain100031https://repository.urosario.edu.co/bitstreams/19559b34-3503-4478-87cb-1a80e19de65e/downloadce129625f825e2285d9b4b0139cc480fMD55THUMBNAILAnalisis_de_costo_utilidad_baricitnib_Gody_Collazos_Ana_Maria.pdf.jpgAnalisis_de_costo_utilidad_baricitnib_Gody_Collazos_Ana_Maria.pdf.jpgGenerated Thumbnailimage/jpeg3342https://repository.urosario.edu.co/bitstreams/4c5afa66-00ff-442f-aa49-00927a425689/downloade41e1e7b670048ceb397f1756f760086MD5610336/41836oai:repository.urosario.edu.co:10336/418362023-12-06 03:03:07.778http://creativecommons.org/licenses/by-nd/4.0/Attribution-NoDerivatives 4.0 Internationalhttps://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.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 |